Thalidomide therapy clinical trial for chronic granulomatous disease-associated intractable granulomatous lesion

Thalidomide therapy clinical trial for chronic granulomatous disease-associated intractable granulomatous lesion - Thalidomide therapy for chronic granulomatous disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009370

Enrollment

Registered

2012-11-21

Start date

2012-12-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic granulomatous disease

Interventions

Oral administration of thalidomide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic granulomatous disease intractable granulomatous lesion

Exclusion criteria

Exclusion criteria: a pregnant woman positive for HIV severe allegy

Design outcomes

Primary

Measure	Time frame
Cure or mitigation of granulomatous lesion	—

Secondary

Measure	Time frame
An effect on susceptibility to infection	—

Countries

Japan

Contacts

Public ContactToshinao Kawai

National Center for Child Heath and Development Department of Human Genetics

kawai-t@ncchd.go.jp03-3416-0181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026